




## Schering-Plough

Telephone: 908-298-4414  
Telefax: 908-298-5379  
richard.chipkin@spcorp.com

Schering-Plough Corporation  
2000 Galloping Hill Road  
Kenilworth, New Jersey 07033-0530  
Telephone (908) 298-4000



January 27, 1998

Robert H. Harris, Ph.D.  
President  
Federal Research Consultants  
2139 Route 35  
Holmdel, NJ 07733

Dear Dr. Harris:

This is in response to the non-confidential data package you sent on your anti-epileptic drug, ADD 234037.

We understand that antagonism at the glycine receptor is a theoretically possible mechanism for the treatment of epilepsy. However, this has not been clinically tested and validated. Therefore, we would prefer to wait until such time as you have completed your Phase II proof-of-efficacy clinical trials before making any commitments. When these have been finished, please contact us again with the results.

Your consideration of Schering-Plough as a licensing partner is appreciated.

Sincerely,

Richard E. Chipkin, Ph.D.  
Director  
Business Development